CAR technology, and synthetic biology more broadly, have the potential to transform the way that medicine is practiced. These strategies have been pioneered using ex vivo cell engineering and have been met with impressive clinical outcomes, however, the practical realities of manufacturing patient-speci...
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell haematologic malignancies. The manufacturing of these T cells typically involves their activation, followed by viral transduction and expansion ex vivo for at leas
The utility of CRISPR-Cas9 technology has led to a surge in applying genome editing approaches to combat a variety of genetic disorders and cancers. In these cases, inherited genetic diseases with known gene mutations can be corrected [1,2]. This technology can also be applied to induce specif...
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
Owing to the heterogeneity of target antigen expression in AML, we took advantage of the versatility of the AdCAR technology, which enables a sequential application of AMs against different target antigens. AMs against CD33, CD123, or CLL-1 were used once at a concentration of 10 ng/ml ...
The SNIP-CARs technology, a protease-regulated platform, utilizes small-molecule drugs such as grazoprevir to modulate the activity of CAR-T cells. This strategy maintains CAR-T cells in an inactive state until they are reactivated by a drug, indicating its potential as a therapeutic safety ...
CAR-T cells are generated by the T cells from patients’ or donors’ blood. After the T cells are expanded and genetically modified, they are reinfused into the patients. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. In this ...
cells, especially those expressing a chimeric antigen receptor (CAR). In this review, we briefly introduce ICI and BiTEs and mainly focus on the CAR T cell technology, which has lately innovated cancer immunotherapy. The latter strategy uses synthetic CARs to more specifically target cancer cells....
Opportunity:New technology for improving therapy efficiency Multiple myeloma therapy options are limited, although CAR T-cells, modified T cells with lymphocyte-like signaling molecules, have shown promise in targeting genes in malignant cells. Clinical trials are curre...
The T cells are selectively enriched or isolated mainly using a magnetic bead-based technology CD3/CD28 beads or CD4 and CD8 beads. Then the cells are activated by culturing with a artificial antigen-presenting cells (APCs, primarily anti-CD3/CD28 beads) followed by transduction using a viral ...